September 12, 2017

Consumption of natural immune strength ingredient EpiCor® fermentate results in beneficial modulation of the gut microbiome and improvement of gastrointestinal comfort and constipation, a new study finds. The research was recently published in BMC Complementary and Alternative Medicine.

“The positive results with EpiCor in this study are very encouraging since an ingredient of this kind has never been evaluated for its role in gut microbiota shifts and effects on common constipation-associated symptoms,” says Massimo Marzorati, Ph.D., PostDoc at Ghent University and co-founder of ProDigest, the contract research organization that conducted the trial. “It’s a remarkable finding to see compelling prebiotic effects in a human study at a dose of only 500 mg per day.”

Read More

December 18, 2013

EpiCor, derived from Saccharomyces cerevisiae, has been shown to have immunomodulating properties in human clinical trials and in vitro. However, the underlying mechanisms behind its immune protection via the gut remain largely unknown. Therefore, the aim of this study was to use an integrated in vitro approach to evaluate the...
Read More

October 30, 2013

Employees at Swanson Health Products report positive results and health benefits from a four-month trial, taking Swanson’s own “EpiCor®” product during one of worst flu seasons in years. Embria Health Sciences, a leader in providing safe and science-based dietary supplement ingredients to the global marketplace, followed-up on its award-winning wellness...
Read More

October 2, 2013

A validated, integrated in vitro approach was used to evaluate the metabolism of EpiCor by intestinal microflora, its modulating effect on the gut microbiota, and its anti-inflammatory activity on human-derived cell lines. Embria Health Sciences, a leader in providing safe and science-based dietary supplement ingredients to the global marketplace, has...
Read More

September 20, 2013

DOWNLOAD PDF Larry E. Robinson, Ph.D. and Stuart Reeves, Ph.D., ARCS, Scientific Affairs A major portion of Embria’s research on EpiCor has been with double-blind, placebo-controlled human trials, looking at clinical endpoints. These results were aimed at demonstrating statistically significant improvements of the consumer’s health, and have been published in...
Read More

« Back